FDA warns CCIC Huatongwei after inspection found copied data and missing records in medical device safety tests.
What happened
FDA inspected the CCIC Huatongwei test facility in Suzhou, China, from January 6 to January 14, 2025, for compliance with Good Laboratory Practice (GLP), the quality rules for nonclinical laboratory studies. FDA found serious violations across medical device safety studies: photocopied and reused source data and signatures, report templates with pre-completed results, records added to the archive just before inspection or missing, specimens and animals not uniquely identified, protocol deviations, and an incomplete Quality Assurance Unit master schedule. The company responded on February 4, 2025, but FDA said the response was inadequate.
What FDA found
The study director did not ensure experimental data were accurately recorded and verified, and records were not archived at study close; FDA cited photocopied source data and signatures, pre-completed report templates, and late or missing archives.
21 CFR 58.33(b), 58.33(f)Histopathology slides and other specimens were not identified by test system, study, nature, and date of collection, and some slide labels were illegible or not traceable to animals.
21 CFR 58.130(c)Animals were not given unique identification; test and control animals were sometimes both labeled only 1 through 5 or 1 through 3.
21 CFR 58.90(d)Studies were not conducted according to protocols; FDA observed guinea pigs without water bottles, feed access problems, and many animals below the protocol-specified 300–500 gram weight.
21 CFR 58.130(a)The Quality Assurance Unit's master schedule was missing 14 of 26 requested studies, had not been updated since September 30, 2024, and lacked required information such as study director, test system, and sponsor.
21 CFR 58.35(b)(1)
What FDA wants
FDA asks the company to provide a written response that fully addresses the specific violations, the conditions that allowed them, how GLP compliance and documentation will be ensured, preventive actions including audit frequency and training, and how effectiveness will be assessed. The provided letter text does not state a response deadline.
Who should pay attention
- device makers relying on CCIC Huatongwei safety studies
- sponsors of premarket submissions using GLP test data
- contract research organizations and test facilities doing device biocompatibility studies
This is a summary. Read the original letter on fda.gov.